MedEffect e-Notice from Health Canada | Second Human Carcinogen in Blood Pressure Medications

On September 12, 2018 Health Canada released a MedEffect Notice advising of an additional recall of certain medications containing Valsartan sourced from Zhejiang Huahai Pharmaceuticals in China.

The original MedEffect notice regarding Valsartan, released on July 13, 2018, warned consumers that several products had been found to be contaminated with N-nitrosodimethylamine (NDMA), a known human carcinogen. In August, the recall grew to include additional products suspected of containing NDMA.

Read the original July 2018 MedEffect Notice

Now, Valsartan products have been found to be contaminated with a second probable human carcinogen called N-nitrosodiethylamine (NDEA). NDEA is formed through chemical reactions from the mechanical processes involved in creating this synthetic product. Toxic to the liver and other organs, Valsartan contamination with NDEA is another example of the pharmaceutical industry’s failings.

Read the full posting